NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) reported third-quarter 2025 financial results and provided updates on its clinical programs, highlighting initial revenue generation and significant regulatory milestones for NRX-100 and NRX-101. The company announced expanded Fast Track designation and an active Expanded Access program for NRX-100 (preservative-free intravenous ketamine) for suicidal depression. The New Drug Application (NDA) for NRX-100 is supported by large-scale real-world ketamine data, and the company is also pursuing an Abbreviated New Drug Application (ANDA) pathway for its preservative-free ketamine product, KETAFREE, which remains on track for a Q2 2026 GDUFA date. NRx noted that the FDA has communicated no major deficiencies in its revised ANDA filing, and the company continues efforts to remove benzethonium chloride from commercial ketamine formulations.
For NRX-101 (oral D-cycloserine/lurasidone), the company has initiated its NDA with Breakthrough Therapy Designation and rolling review. This is supported by real-world evidence indicating that D-cycloserine more than doubles the antidepressant and antisuicidal effect of transcranial magnetic stimulation (TMS). A confirmatory Phase 3 trial is expected to begin in early 2026. Additionally, NRx is expanding its HOPE delivery platform with plans for additional facilities in Florida.
The company's first revenue-generating activities mark a transition from a purely clinical-stage biopharmaceutical company to one with commercial potential. The progress of NRX-100 and NRX-101 addresses a critical unmet need in treating suicidal depression, a condition with limited approved therapies. The FDA's Fast Track and Breakthrough Therapy designations underscore the potential of these treatments to offer significant improvements over existing options. The use of real-world evidence in regulatory filings is a notable approach that could accelerate patient access to these therapies. Investors can find more information in the company's newsroom at https://ibn.fm/NRXP.
